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ABC efflux transporters are a key factor leading to multidrug resistance in
cancer. Overexpression of these transporters significantly decreases the efficacy of
anti-cancer drugs. Along with selection and induction, drug resistance may be trans-
ferred between cells, which is the focus of this dissertaion. Specifically, we consider
the intercellular transfer of P-glycoprotein (P-gp), a well-known ABC transporter
that was shown to confer resistance to many common chemotherapeutic drugs.
In a recent paper, Durán et al. studied the dynamics of mixed cultures of
resistant and sensitive NCI-H460 (human non-small cell lung cancer) cell lines [1].
As expected, the experimental data showed a gradual increase in the percentage of
resistance cells and a decrease in the percentage of sensitive cells. The experimental
work was accompanied with a mathematical model that assumed P-gp transfer
from resistant cells to sensitive cells, rendering them temporarily resistant. The
mathematical model provided a reasonable fit to the experimental data.
In this dissertation we develop three new mathematical model for the transfer
of drug resistance between cancer cells. Our first model is based on incorporating
a resistance phenotype into a model of cancer growth [2]. The resulting model
for P-gp transfer, written as a system of integro-differential equations, follows the
dynamics of proliferating, quiescent, and apoptotic cells, with a varying resistance
phenotype. We show that this model provides a good match to the dynamics of the
experimental data of [1]. The mathematical model further suggests that resistant
cancer cells have a slower division rate than the sensitive cells.
Our second model is a reaction-diffusion model with sensitive, resistant, and
temporarily resistant cancer cells occupying a 2-dimensional space. We use this
model as another extension of [1]. We show that this model, with competition and
diffusion in space, provides an even better fit to the experimental data [1]. We
incorporate a cytotoxic drug and study the effects of varying treatment protocols
on the size and makeup of the tumor. We show that constant infusion leads to a
small but highly resistant tumor, while small doses do not do enough to control the
overall growth of the tumor.
Our final model extends [3], an integro-differential equation with resistance
modeled as a continuous variable and a Boltzmann type integral describing the
transfer of P-gp expression. We again extend the model into a 2-dimensional spatial
domain and incorporate competition inhibited growth. The resulting model, written
as a single partial differential equation, shows that over time the resistance transfer
leads to a uniform distribution of resistance levels, which is consisten with the results
of [3]. We include a cytotoxic agent and determine that, as with our second model, it
alone cannot successfully eradicate the tumor. We briefly present a second extension
wherein we include two distinct transfer rules. We show that there is no qualitative
difference between the single transfer rule and the two-transfer rule model.
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Chapter 1: Introduction
The work in this dissertation uses mathematical models to study the transfer
of a specific protein, P-glycoprotein, between cells and how this transfer affects
multidrug resistance in cancer. Since this work integrates mathematics and cancer
biology, we begin with a discussion of the biology in our models. This opening
chapter will give a brief primer of the mechanisms of cancer.
1.1 Biology of Cancer
Cancer is a worldwide public health issue and the second leading cause of
death in the United States [4]. In the United States alone, there were an estimated
1.5 million new cases in 2016, with almost 600,000 expected deaths [4]. The lifetime
probability of being diagnosed with some type of invasive cancer hovers around 40%,
with that number slightly higher for men and slightly lower for women [4]. Cancer
is a group of diseases arising from the loss of control of cell growth [5]. Uninhibited
cellular growth is the most prevalent marker of cancer. Malfunctions in the systems
that regulate this growth can happen anywhere in the body. This explains the many
different types of cancers, from blood cancers including leukemias to solid tumors
including the most common- breast, lung, and prostrate cancers [4].
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In order to achieve unlimited growth, apoptosis must be at least partially inhib-
ited [6,7]. Apoptosis is the inherent mechanism used in cellular self-destruction [8].
Cancer occurs when a series of mutations in the proteins constructing cellular growth
control systems cause the loss of appropriate functionality [5]. These mutations can
be genetic, occuring during the copying of DNA, as well as epigenetic, induced by
outside factors or events [5, 9]. Common carcinogens, such as smoking, radioactive
materials, and sunburns, are activities and events that can damage DNA and cause
mutations [5,10,11]. The uninhibited growth can eventually disrupt organ function,
leading to death [12]. Interestingly, since many cancers develop after child-bearing
years, there is no evolutionary pressure to limit these mutations [5].
With the improvement in treatment protocols and therapies, several cancers
have high 5-year survival rates if diagnosed early. For example, the average 5-year
survival rate for breast cancer is 90% [13]. Once cancerous cells have metastasized
and a secondary tumor begins growing elsewhere, the 5-year survival rate plum-
mets. If a breast tumor has undergone metastasis, the 5-year survival rate drops to
26% [13]. Cancer cells are also able to vascularize through angiogenesis, the process
of creating their own blood vessels to sustain large tumors [14,15].
Surgery, chemotherapy, radiotherapy, and immunotherapy are currently the
four main protocols for treatment. Some form of surgery has been prevalent since
the time of the ancient Greeks, where Hippocrates first identified a tumor as a
karkinos [16]. Surgical removal of a solid tumor is still the most common method
but it is now known that surgery alone might not deliver a cure. There may be
cancer cells that are not removed through surgery and are able to regrow the tumor,
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so chemotherapy and radiotherapy is used as an adjuvant therapy. If a tumor is too
large or not sufficiently isolated, chemotherapy may be used first as neoadjuvant
therapy to shrink the tumor to a manageable size for surgery [17].
Chemotherapy is the delivery of a poisonous chemical compound used to tar-
get cells. Most drugs slow down or stop mitosis [18–20]. While this is the most
straightforward way of decreasing the tumor load, it often cannot eradicate the
tumor completely. The main reason for treatment failure is due to the develop-
ment of drug resistance, wherein cancer cells evolve to become less affected by the
chemotherapeutic agent [21]. Radiation therapy, or radiotherapy, damages the can-
cer cell DNA through ionizing radiation, leading to apoptosis [22,23]. Immunother-
apy prods the immune system, either directly or indirectly, to attack and suppress
tumor growth [24, 25]. The immune response may act by slowing down the pro-
liferation and growth of cancer cells [25]. Consequently, immunotherapy does not
yield drug resistance in the way that chemotherapy does [26]. There are now well
over 100 chemotherapeutic agents that can be used in combinations and alongside
immunotherapies.
In all cases, drugs target the cell cycle. Cells in quiescence are not affected
until they enter an active proliferation stage. Most therapies do not differentiate
between cancerous and healthy cells. They are adjusted to the rate of proliferation
of cancer cells, which is why fast proliferating cells such as hair cells are adversely
affected by cancer treatments [27]. There is a balance between doses that are enough
to affect the tumor and not too high to cause substantial damage to healthy tissues.
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1.2 Drug Resistance
Figure 1.1: The most prevalent mechanisms by which a cancer cell inherits and
exhibits drug resistance. Figure adapted from [28].
Resistance of tumor cells to anti-cancer drugs is one of the most important chal-
lenges facing oncologists. The Norton-Simon hypothesis states that the reduction
in tumor volume resulting from chemotherapy is proportional to the unperturbed
rate of growth of a tumor of the same size [29, 30]. Unfortunately drug resistance
can slow down this reduction. Drug resistance can be caused by intrinsic factors,
such as location in the tumor, or by genetic events such as mutations [31]. Mul-
tidrug resistance has been previously explained as an overexpression of ABCB1 but
there are a plethora of other mechanisms at play as well, including decreased drug
uptake and evasion of apoptosis [31]. As drugs are administered, cancer cells can
mutate and their progeny become more resistant and the drugs less effective [32].
Understanding the mechanisms that cause and propagate resistance is paramount
to devising methods for overcoming it.
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When administering drugs to cancer patients there are two main types of drugs:
(i) cytostatic drugs, which target cancer cells by slowing down their proliferation rate
and (ii) cytotoxic drugs, which kill the cells. Both cytostatic and cytotoxic drugs
can harm healthy cells yet have an increased effect on tumor cells, although there
are cytostatic drugs that act on the tumor environment which can avoid uneccessary
harm to healthy cells [33]. Not all cancer cells exhibit the same traits, genotypically
or phenotypically, and so tumor heterogeneity is very important in understanding
the effects of both types of drugs. This dissertation will focus on one specific protein
overexpression that causes resistance to multiple drugs simultaneously.
Antineoplastic resistance is often the key impediment to effective cancer treat-
ment. Though advances in early detection have increased survival rates across
several cancer subtypes, resistance to chemotherapy is prevalent [34, 35], and the
majority of patients will relapse at a certain point following treatment. Therapeutic
failure may be attributed to intrinsic tumor heterogeneity prior to therapy (e.g.,
spatial localization of cancer cells within a tumor, initial cellular genetic landscape,
cell-cycle length variations, etc.) or induced tumor heterogeneity after initiation of
therapy, such as altered molecular signaling, genetic modification, and microenvi-
ronmental alterations.
Development of resistance to one drug can also lead to resistance to other struc-
turally and mechanistically unrelated drugs, a phenomenon referred to as multidrug
resistance (MDR). MDR can be understood through different biological factors and
is often identified with drug efflux [36]. There has been increasing evidence that
drug cellular uptake is regulated by transport proteins expressed on the cellular
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membrane, which are responsible for drug transport across the plasma membrane
and throughout the cell. One such example is the family of ABC (ATP Binding
Cassette) transporters. ABC transporters can pump away chemotherapeutic agents,
which allow certain cells to withstand the drugs’ cytotoxic effect [31]. These non
drug-specific transporters provide a mechanism for the cells to resist unrelated drugs,
which then leads to a chemotherapy breakdown. While ABC transporters have im-
portant roles in the importation of nutrients and exportation of toxic molecules [37],
their overexpression is a serious obstacle in anti-cancer therapies.
1.2.1 P-glycoprotein
P-glycoprotein (P-gp), a product of the ABCB1 (mdr1 ) gene, is a well-known
ABC transporter that correlates with MDR [38, 39]. It has been shown to confer
resistance to many common chemotherapeutic drugs [40–43] and is expressed in
many human cancers [44]. In normal human tissues it is concentrated in cells in
the liver, pancreas, kidney, colon, and jejunum [45]. P-gp targets xenobiotics and
there is a lengthy list of substrates it can expel, including common anti-cancer drugs
doxorubicin, paclitaxel, and imatinib. The MDR1 gene encodes the transmembrane
P-gp pump that cells use to excrete structurally and chemically diverse drugs [8].
A drug molecule is bound by the P-gp’s cytoplasmic domain; the protein subse-
quently uses ATP hydrolysis and opens itself to the extracellular space and expels
the drug molecule [8]. The overexpression of P-gp can lead to resistance of more
than 100 times higher than normal cells [46]. Two studies in 2005 showed resistant
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populations can spread their resistance to sensitive cells [47, 48]. More recently,
intracellular membrane nanotubes were shown to carry P-gp between neighboring
cells [44].
Drug resistance is often a multifactorial, complex process that arises through a
series of genetic and non-genetic changes across multiple cancers. Such changes can
be the consequence of drug administration (therapy-dependent), or can be acquired
independently of any drug (therapy-independent). The focus of this work is on drug
resistance that may be transferred between cells, e.g., via cell-to-cell communication.
1.3 Setup of the Dissertation
In this dissertation we develop new mathematical models for the transfer of
drug resistance between cancer cells. Our first model, studied in Chapter 3, is
based on incorporating a resistance phenotype into a model of cancer growth [2].
The resulting model for P-gp transfer, written as a system of integro-differential
equations, follows the dynamics of proliferating, quiescent, and apoptotic cells, with
a varying resistance phenotype. We show that this model provides a good match
to the dynamics of the experimental data of [1]. The mathematical model further
suggests that resistant cancer cells have a slower division rate than the sensitive
cells.
The second model, studied in Chapter 4, is a set of reaction-diffusion equations
governing the growth of sensitive and resistant cancer cells in the presence of a
chemotherapeutic agent. Since the resistant cells in the experiments from [1] were
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induced through doses of doxorubicin, that is the drug we consider here. We allow
the drug efflux action of the P-gp pumps to affect the diffusion of the drug and
incorporate a temporarily resistant phenotype. We study the effects of constant
infusion versus on/off treatment of the drug. We show the lack of existence of an
optimal therapy under the constraints of the model.
Our third model, studied in Chapter 5, continues the work of [3,49] in studying
a set of Boltzmann type integro differential equations to investigate resistance as a
continuous variable. We extend this measure by including two spatial dimensions
and density-dependent proliferation. The resulting reaction-diffusion equation in-
corporates the reaction as an integral term summing over all the of nearby transfers
of resistance that result in a specific resistance level. We show that the model agrees
with the findings of [3]. The model is then extended by incorporating the effects of
the cytotoxic drug doxorubicin. We study different protocols and demonstrate that
there is no optimal way to control the propagation of resistance.
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Chapter 2: Mathematical Models of Multidrug Resistance
Early mathematical models of drug resistance in cancer are due to Goldie &
Coldman [50]. Their work is based on a probabilistic model in which the presence of
a drug leads to cellular mutations which results in drug resistance. The approach of
Goldie & Coldman was not immediately widely accepted. Rosen [51] believed that
resistance was independent of dose and proposed a model for cellular competition,
arguing that resistance is selected through competition and is not induced by the
drug, as Goldie & Coldman had argued. To emphasize his point, Rosen used for [51]
the same title used by Goldie & Coldman a year earlier. It has been shown since
that selection and induction can coexist and both lead to drug resistance [52–55].




Panetta [56] developed a heterogeneous tumor model with induced resistance:
dx
dt
= [r1 − d1(t)]x, (2.1a)
dy
dt
= b1d1(t)x+ [r2 − d2(t)]y. (2.1b)
In this model x(t) represents sensitive cell mass and y(t) represents resistant
cell mass. b1 represents the resistant cell induction rate due to the effects of the
chemotherapy drug d1. A second function of time, d2, represents the effect of the
drug on resistant cells, so d2 ≡ 0 if they are completely resistant. Both sets of cells
exhibit exponential growth. Panetta used this model to study treatment protocols
and find at what point the tumor stops regressing with the drug.
Jackson & Byrne [14] added a spatial component through a radially symmetric
reaction-diffusion model without induction from the drug:
∂d
∂t
+∇ · (ud) = ∇ · (D(r)∇d) + Γ(r)(db(t)− d)− λd, (2.2a)
∂p
∂t
+∇ · (up) = Dp∆p+ Fp(p)− Cp(d, p), (2.2b)
∂q
∂t
+∇ · (uq) = Dq∆q + Fq(q)− Cq(d, q). (2.2c)
This model includes an equation for the drug, d(t), with diffusion term D(r)
assuming that the distance from the center of the tumor may affect diffusion. Γ(r) is
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the rate coefficient of blood-tissue transfer and db(t) is the prescribed drug concen-
tration in the vasculature. p(t) represents the sensitive cells and q(t) the resistant
cells. Fp and Fq are proliferation rates and the terms Cp and Cq are the effect
of chemotherapy. Jackson & Byrne showed that the effectiveness of the treatment
protocols depended on the initial make-ups of the tumor.
MDR has been studied in connection with tumor heterogeneity [14, 57–59].
Lorz et al. [59] modeled resistance as a continuous variable and demonstrated that
the presence of a cytotoxic agent leads to diminished heterogeneity and a population
of overwhelmingly resistant cells. Lavi et al. extended the approach of Lorz to model
intratumoral heterogeneity [57]. For a further review on mathematical models of
MDR we refer to [58] and the references therein.
2.2 Optimal Treatment
Mathematical tools can be used to identify treatment strategies that optimize
certain aspects, such as minimizing the overall tumor load or minimizing the amount
of drug.
Panetta [56] studied a sequential drug administration and used the ratio of
resistant to sensitive cells to analytically show when to switch from one drug to
another. Goldie & Coldman [60] attempted to determine whether sequential or
combination therapies are more effective. While combination therapy may be im-
practical due to high toxicity, they determined that it is the optimal option. Lorz et
al. [59] found a specific parameter set for which resistance will occur based on the
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amount of drug dose, and then in [61] studied a combination of cytotoxic and cy-
tostatic drugs. They showed intra-tumor heterogeneity is decreased under constant
infusion of a cytotoxic drug, with drug resistance levels rising dramatically.
In the early 2000s De Pillis & Radunskaya studied optimal control within
models of cancer treatment [62–64]. They emphasize the role of the immune system
in mediating the growth of the tumor. Their model from [63] is written as:
dN
dt
= r2N(1− b2N)− c4TN − a3(1− e−u)N, (2.3a)
dT
dt






− c1IT − d1I − a1(1− e−u)I, (2.3c)
du
dt
= v(t)− d2u. (2.3d)
N(t) is the number of normal cells, T(t) the tumor cells, I(t) the immune cells,
and u(t) the drug. There is competition between the normal cells and tumor cells.
Interaction between the immune cells and the tumor cells can lead to inactivation
of immune cells but also can lead to the death of the tumor cells. The presence
of tumor cells stimulates the immune response so immune cells exhibit nonlinear
growth when interacting with tumor cells. Finally, all the cells are affected by the
existence of the drug u with a fractional cell kill term. They show that the optimal
drug treatment protocol is ’bang-bang’, where either a full dose or zero dose is given
for each time step.
In the last 10-15 years Ledzewicz & Schättler have been developing optimal
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control theory and its application to anti-cancer therapies. In [65] they consider an
ODE model with sensitive compartment S(t) and resistant compartment R(t):
dS
dt
= −aS + (2− q)aS + rcR, (2.4a)
dR
dt
= −cR + (2− r)cR + qaS. (2.4b)
The first terms on the right are the deaths of the mother cells. The second
terms include the progeny along with the return mutations back from resistant to
sensitive (and vice versa). Inclusion of a constant drug dose u changes the repre-
sentation to be as follows:
dS
dt
= −aS + (1− u)(2− q)aS + rcR, (2.5a)
dR
dt
= −cR + (2− r)cR + (1− u)qaS. (2.5b)





L(N, u)dt+ φ(T,N(T )). (2.6)
In any model the necessary conditions, including minimum and transversality condi-
tions, for the existence of an optimal control are given by the Pontryagin Maximum
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Principle [66, 67]. For the type of functionals 2.6, Ledzewicz & Schättler show the
existence of optimal solutions and conditions for singular controls. For more detail
we refer to their books [67,68].
2.3 P-Glycoprotein
Several mathematical models for specific mechanisms of resistance have been
derived and studied. As mentioned in 1.2.1, P-glycoprotein is one of the most well-
known of these mechanisms. It is an ABC transporter than allows cells to excrete a
variety of anti-cancer drugs. Michelson and Slate [69] derived a model incorporating
adenosine triphosphate (ATP) and adenosine biphosphate (ADP). They note that
the efflux generated by Pgp overexpression is only possible when ATP is also present
since it needs to bond with p170. A later work [70] includes the presence of an
inhibitor. A biophysical model was introduced by Panagiotopoulou et. al [71].
They show that the internal makeup of the tumor and the interaction between the
drug molecular weight and the membrane are drivers of MDR. These factors impact
the chance of an interaction between the drug drug and a protein transporter.
Relatively little attention has been given in the mathematical community to
modeling the transfer of drug resistance between cells. A recent work by Durán
et al. [1], derived two models for P-gp transfer assuming P-gp expression has a
discrete characteristic: P-gp in a cell is either overexpressed or not. These models
are written as a coupled system of ordinary differential equations (ODEs) describing
the behavior of sensitive cells (S), resistant cells (R), and temporarily resistant cells
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(SR). Interaction between sensitive and resistant cells allows the resistant population
to transfer P-gp to the sensitive cells, which become temporarily resistant. Since
this is a phenotypic change, the progenies of these cells revert back to a sensitive
state. The resistant cells are not affected by the interaction and exhibit logistic










































A second model proposed in [1] extends (2.7 by assuming that P-gp is trans-
fered through the shedding of microvessicles (MVs) by resistant cells. MVs are
small particles that are released via plasma membrane blebbing. In addition to
their role in mediating inflammation, coagulation, and vascular homeostasis, they
are important mediators of MDR, as they facilitate cell-to-cell communication and
can deliver proteins between cells [72]. The intake of MVs by sensitive cells may
lead to temporary resistance. A system of ODEs that incorporates the role of MVs
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In addition to introducing the mathematical models, Durán et al. conducted
experiments on mixed cultures of NCI-H460 cell line (human non-small cell lung
carcinoma) cells and NCI-H460/R resistant cells that were selected from NCI-H460
cells after three months of doxorubicin selective pressure. Cultures of only sensitive,
only resistant, and mixed cultures were seeded in ratios 1:1, 3:1, and 7:1 sensitive to
resistant cells and their growth was followed over time. Flow cytometry was used to
measure P-gp expression levels at time points 0, 24, 48, 72, and 96 hours, and P-gp
transfer was analyzed every 24 hours. The experimental data was used to calibrate
the parameters of the mathematical models.
Pasquier et al. [49] studied cell-to-cell transfers of P-gp in co-cultures com-
bining a sensitive human breast cancer MCF-7 cell line, and a P-gp overexpressed
variant, selected for its resistance towards doxorubicin. Pasquier et al. derived
a Boltzmann type integro-partial differential equation structured by a continuum
variable corresponding to P-gp activity. The model was used to quantify the trans-
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fer of P-gp activity and, in conjunction with the experimental data, to confirm the
cell-to-cell transfer of functional P-gp. p is the continuous variable that measures
resistance, with a density dependent growth term along with a transfer term T that
encompasses all transfers that end with resistance level p.
∂u(t, p)
∂t
= ρ(p)u(t, p) + 2τ(T (u(t, ·))− u(t, p)), (2.9a)
u(0, p) = u0(p) ∈ L1+(1, 104). (2.9b)
Here, the transfer operator T (u)(p) is defined as
T (u)(p) =
∫∞




A study extending this work to multiple transfer rules has been recently pub-
lished in [3]. This study is the motivation for Chapter 5.
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Chapter 3: A Cell-Cycle Model of P-gp Transfer
3.1 Introduction
In this chapter we study an extension of the Durán et al. [1] model (2.7) that









































Since the model (3.1) produces more accurate results than the alternate Durán
et al. model (2.8), we use (3.1) as the reference model to which we compare our
results.
In addition to introducing the mathematical models, Durán et al. conducted
experiments on mixed cultures of NCI-H460 cell line (human non-small cell lung
carcinoma) cells and NCI-H460/R resistant cells that were selected from NCI-H460
cells after three months of doxorubicin selective pressure. Cultures of only sensitive,
only resistant, and mixed cultures were seeded in ratios 1:1, 3:1, and 7:1 sensitive to
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resistant cells and their growth was followed over time. Flow cytometry was used to
measure P-gp expression levels at time points 0, 24, 48, 72, and 96 hours, and P-gp
transfer was analyzed every 24 hours. The experimental data was used to calibrate
the parameters of the mathematical models.
In Fig. 3.1 we show the dynamics of the fractions of sensitive and resistant
cells over time for different seeding ratios. Shown are the experimental results and
simulations of (3.1). Clearly, while some general trends are common between the
experimental data and the simulations, the fit is not optimal. For example, it takes
about half the simulation time (50 hours) for the simulations to begin following
the general growth trend of the data. Intriguingly, the microvessicle model, (2.8),
produces a worse fit to the experimental data than model (3.1), [1].






















































Figure 3.1: Fractions of resistant (left) and sensitive (right) cells over time. Dots cor-
respond to the experimental data of [1]. Solid lines are simulations of the model (3.1)
of [1].
Our goal in this chapter is to develop a new mathematical model for the
transfer of drug resistance between cancer cell subpopulations that will provide a
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better fit to the experimental data of [1]. Since neither the experiments nor models
of [1] include a drug, we propose a model that incorporates no action of a drug.
Building on the idea of separating the cancer cells into three subtypes: sensitive,
resistant, and temporary resistant, we aim at providing a more accurate model by
better capturing the cancer growth dynamics. Accordingly, we incorporate the three
subpopulations into a cancer growth model of Greene et al. [2]. This model considers
cells in three states: quiescent, proliferating, and apoptotic, with transition rates
that depend on the cellular density. The model was shown in [2] to provide an
accurate fit to the growth dynamics of OVCAR-8, an ovarian cancer cell line. By
incorporating drug resistance and a mechanism of resistance transfer into the model
of [2] we provide a better match to the NCI-H460 experimental data of [1].
The structure of this chapter is as follows: In section 3.2 we derive our new
model for the P-gp transfer between cancer cells. Simulations of the model and
a sensitivity study of the model parameters are shown in section 3.3. Concluding
remarks are provided in section 3.4. The results presented in this chapter were
published in [73].
3.2 Our Model
Our starting point is the cancer growth model of Greene et al. [2]. In this
model, cancer cells are divided into three compartments: proliferating (P ), quies-
cent (Q), and apoptotic (A) cells (see Fig. 3.2). The transition rates between the
compartments are assumed to depend on the cellular density. Quiescent cells can
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either remain quiescent, start proliferating, or commit apoptosis. Proliferating cells
complete the cell cycle unless they transition to apoptosis. Once the cell cycle is
completed and a cell divides, both cells transition to the quiescent compartment.
Once a cell commits to apoptosis, it stays in the apoptotic compartment until it
dies. The duration of the cell-cycle is assumed to be normally distributed, and the
time spent in the apoptotic cycle follows a gamma distribution. The model was
designed to predict variations in growth as a function of the intrinsic heterogeneity
originating from the varying duration of the cell-cycle and apoptosis. The model
parameters were fitted in [2] to experimental data coming from OVCAR-8, an ovar-
ian cancer cell line. However, the model is generic and could be used to describe
the growth of other cancers.
To describe resistance transfer during cancer growth, we incorporate drug
resistance into the PQA model of [2]. We split the quiescent compartment, Q, into
sensitive (Sq) and resistant (Rq) subtypes. The proliferative compartment, P , is
also divided into sensitive (Sp) and resistant (Rp) cells. In addition, the proliferative
compartment also includes a temporarily resistant phenotype (Tp). Similarly to the
original PQA model, we leave the apoptotic stage as a single compartment since
we assume that cells that enter apoptosis are committed to it. In our model the
transfer of P-gp happens as the quiescent cells start proliferating. We assume that
once cells have begun proliferating they maintain their phenotype. We define ξ
to be the fraction of sensitive quiescent cells that become temporarily resistant as
they transition to a proliferating state. Since P-gp transfer only leads to temporary
resistance we stipulate that the progeny of temporarily resistant cells are sensitive
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Figure 3.2: Diagram representing the PQA model from [2]. Here, P denotes the
proliferative compartment, with NP (t) cells at time t. Proliferating cells can either
transition to apoptosis, A, or to quiescence Q, upon completion of the cell-cycle.
At time t there are NA(t) apoptotic cells and NQ(t) quiescent cells. Quiescent cells
can either transition to P with rate αp(t), or to A with rate αaq(t). The implicit
transition rates due to the completion of the cell cycles are shown in dashed lines.
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cells. The amount of P-gp in a temporarily resistant proliferating cell is divided
between the daughter cells so we consider both offsprings to be sensitive. Clearly,
a more accurate model can include a larger range of resistance levels (temporary or
permanent). With the rather limited experimental data at our disposal, we prefer
the simpler approach presented here. A diagram corresponding to our model is
shown in Fig. 3.3.
Two equivalent model formulations were introduced in [2]: a stochastic agent-
based model, and an integro-differential (IDE) model. In this chapter we choose to
work with the IDE model and extend it to incorporate drug resistance. Our model
equations are written as a system of six IDEs. The first two equations provide the










































Figure 3.3: Diagram representing the proposed model (3.2)–(3.4). The quiescent
cells, Q, are divided into two types: resistant quiescent cells, Rq(t), sensitive qui-
escent cells, Sq(t). The proliferating cells, P , are divided into three compartments:
resistant proliferating cells, Rp(t), temporary resistant proliferating cells, Tp(t), and
sensitive proliferating cells, Sp(t). Resistant proliferating cells become resistant qui-
escent cells upon completing the cell cycle. Sensitive and temporary resistant pro-
liferating cells become sensitive quiescent cells when they complete the cell cycle.
Proliferating and quiescent cells may become apoptotic cells, a compartment they
leave only when they die. The time spent in the proliferating cycle is normally
distributed with parameters that may vary depending on whether the proliferating
cells are resistant or not.
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Three equations follow the dynamics of proliferating cells:
dSp
dt









































A sixth equation describes the dynamics of apoptotic cells:
dA
dt






The first equation in (3.2) follows the dynamics of the sensitive quiescent cells,
Sq. The first term on the RHS, −αspSq(t), corresponds to the fraction of cells lost as
a result of the transition to the proliferative compartment P . This term encompasses
cells that stay sensitive and those that become temporarily resistant. The second













corresponds to the increase in Sq due to the progeny of the sensitive proliferat-
ing cells. We assume that all proliferating cells originated from quiescent cells, so
αspSq(t∗) includes all sensitive proliferating cells. There are two such terms, the first
(with 1− ξ) corresponds to sensitive proliferating cells that competed their prolifer-
ating cycle (hence the factor of 2 in front of the integral). The second term (with ξ)
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corresponds to temporary resistant cells that completed their proliferation cycle and
became sensitive quiescent cells. We assume that the time spent in the proliferative








The term 1 −
∫ t
t∗
αasp(s)ds describes the cells in the cell cycle that did not move
to apoptosis before completing the proliferation cycle, where t corresponds to the
time cells entered the proliferating compartment. Overall, the full integral accounts
for the progeny for the proliferating cells whose time spent in the cell cycle has
come to an end. The somewhat complex bookkeeping in this model (expressed by
the integral terms) is due to assuming a distribution on the time cells may take to
proliferate (and die), as opposed to the more standard approach of assuming that
these values are constant. We allow the proliferation time, characterized by the
parameters of the normal distribution, µ and σ, to differ between the resistant and
sensitive populations since resistant cells may have a slower proliferation rate [74].
If these parameters are assumed to be identical for resistant and sensitive cells, both
integrals terms can be combined into one term.
The second equation in (3.2) describes the dynamics of the resistant quiescent
population, Rq. The RHS is similar to the first equation, with a loss term due to
transition into the cell cycle and another loss term due to transition to apoptosis.
Since we assume that these cells exhibit a resistant genotype we do not allow them
to lose their resistance and so the integral term represents the progeny from all the
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resistant cells in the cell cycle that have their time span end at a certain time t.
Similar equations are provided for the three types of cells in the proliferative
compartment, described in (3.3). The first term on the RHS of the first equation
for the sensitive proliferative population, Sp, represents the fraction of sensitive qui-
escent cells that started proliferating but stayed sensitive and did not acquire any
temporary resistance. We include an apoptotic term and the same integral seen
in (3.2), representing the end of the cell cycle in which each proliferating cell that
has not transitioned into apoptosis divides into two new quiescent cells. The second
equation, for the resistant proliferating cells, Rp, includes a transition term from
resistant quiescent to resistant proliferative and another term representing transi-
tion to apoptosis term with the integral from the second equation in (3.2) showing
the loss due to division at the end of the cell cycle, as cells transition to the resis-
tant quiescent cells compartment. The third equation, for the temporary resistant
proliferating cells, Tp, has the same three types of terms, with ξ multiplying the
transition term from sensitive quiescent showing the fraction of cells that acquired
temporary resistance.
Finally, (3.4) describes the apoptotic compartment. Once cells start apoptosis
we no longer distinguish between resistant or sensitive cells. Equation (3.4) includes
the five growth terms that correspond to the transitions from all compartments in







with λ and γ the rate and shape parameters of the apoptotic process and Γ(·) the
gamma function. Once cells complete the time committed to apoptosis, they are
removed from the system. The integral term describes this removal for all cells
that die at time t. In this term we denote the total loss by αN(t) := αasqSq(t) +
αarqRq(t) + αaspSp(t) + αarpRp(t) + αatpTp(t).
The transitions rates from [2] are functions of β(ρ) and d, the equilibrium
fraction of proliferating cells and the fraction in apoptosis, which we take to be
constant. We set βm and ρm as the maxima for β, and ρ, respectively, and define
β(ρ) =
{ βme−a(ρ−ρm)2/ρ(1+ε−ρ)2 if 0 < ρ < 1 + ε,
0 otherwise.
(3.7)





We define the transitions αsp(t) and αrp(t) as the rates from sensitive qui-
escent to sensitive or temporarily resistant proliferating and resistant quiescent to
resistant proliferating, respectively. We make the assumption that P-gp expression
is independent of the transition. Hence, we set αsp(t) = αrp(t). The intrinsic death
terms from quiescent to apoptotic are αasq(t) and αarq(t), with the death terms
from proliferative to apoptotic being αasp(t),αarp(t), and αatp(t). We again con-
sider no effect of P-gp transfer on these terms and thus have αasq(t) = αarq(t) and
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αasp(t) = αarp(t) = αatp(t). These transition rates are shown below.












Here, Q(t), P (t), and A(t) are the total number of cells in each respective compart-
ment and N(t) = Q(t) +P (t) +A(t) with ρ(t) = N(t)/K for a carrying capacity K.
The transition from Q to P is a function of the difference between the current prolif-
erative population, P (t), and the desired (or equilibrium) proliferative population,
β(ρ(t))N(t). Similarly, the transitions into apoptosis are functions of the difference
between current apoptotic population A(t), and desired fraction in apoptosis dN(t),
where d is taken to be a small constant < 0.05. c is the cellular reaction rate and γ




We use a four-step explicit Adams-Bashforth (AB) method to approximate
solutions of the system (3.2)–(3.4). This solver is chosen since it does not require
temporary intermediate values, which simplifies the calculations due to the presence
of the integral terms. The method can be written as
yn+1 = yn +
∆t
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(55fn − 59fn−1 + 37fn−2 − 9fn−3), (3.12)
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we can approximate I(t+ ∆t, t∗) with













h2(s)ds+ h2(t)∆t = I(t, t∗) + h2(t)∆t.
(3.14)
Equation (3.14) requires only one function evaluation. The complete integral (3.13)














(h1(t, tk)(1− I(t, tk))
+ h1(t, tk+1)(1− I(t, tk+1))) ,
(3.15)
with tk the kth point and N the size of the discretization.
In our simulations, we optimized the model parameters using Matlab’s non-
linear least squares function, fitting the solution of (3.2)–(3.4) to the experimental
data of [1]. We set d = 0.03, which corresponds to the same fraction of cells in
apoptosis from [2]. The full list of parameters and their ranges is given in Table 3.1.
The optimal values used in the simulations are given in Table 3.2 for the case in
which resistant cells and sensitive cells have different growth parameters, and in
Table 3.3 for the case when the growth parameters are identical for both sensitive
and resistant cells.
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Table 3.1: Parameter Values & Descriptions
Parameter Range Description Reference
t [0,180] (hours) Time [1]
µ1 [10,∞) (hours) Mean length of (sensitive) cell cycle [2]
σ1 [0,10] (hours) Standard deviation of (sensitive) cell cycle [2]
µ2 [12,∞) (hours) Mean length of (resistant) cell cycle [2]
σ2 [0,10] (hours) Standard deviation of (sensitive) cell cycle [2]
ω 4.9436 Shape parameter of entire apoptotic process [2]
λ 0.19117 (per hour) Rate parameter of entire apoptotic process [2]
ρ(t) [0,∞) Density of cells at time t [2]
K 7.5× 105 Carrying capacity [1]
d [0.01,0.05] Fraction of cells in apoptosis [2]
β(ρ) [0,1] Fraction in cell cycle as a function of density [2]
βm [0,1] Maximum of β(ρ) [2]
ρm [0,1] Maximizing density of β(ρ) [2]
ε [0,∞) Parameter governing shape of β(ρ) [2]
c [0,∞) (per hour) Cellular reaction rate [2]
γ [0,1] Rate difference between αap and αaq [2]
ξ [0,1] Fraction of cells becoming temporarily resistant
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Table 3.2: Parameters values used in simulations with different growth parameters
for the sensitive and resistant cells
Parameter µ1 σ1 µ2 σ2 ω λ K
Value 10.0258 9.2818 12.0033 5.8467 4.9436 0.19117 7× 105
Parameter d βm ρm ε c γ ξ
Value 0.03 0.8 0.0458 0 15.4753 0.8331 0.0412
Table 3.3: Parameters Values Used in Simulations with identical growth parameters
for the sensitive and resistant cells
Parameter µ1 σ1 µ2 σ2 ω λ K
Value 10.2365 4.3263 10.2365 4.3263 4.9436 0.19117 7× 105
Parameter d βm ρm ε c γ ξ
Value 0.03 0.8 0.2 0.2346 1.6732 0.5011 0.4828
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3.3.2 Simulations






















Figure 3.4: The dynamics of the total population of resistant and sensitive cells
over 200 hours simulated with (3.2)–(3.4). We consider the three initial ratios of
sensitive to resistant cells: 1:1, 3:1, and 7:1.
Our first simulations show the total population of sensitive and resistant cells
over time for three different initial conditions. Following the setup of [1] we run
separate simulations for a 1:1, 3:1, and 7:1 initial ratio of sensitive to resistant cells.
The resistant subtype, as described in [1], are cells that have been given Doxorubicin
for three months and survived. At time t = 0 all cells are assumed to be quiescent.
Fig. 3.4 shows growth up to a carrying capacity and then a small decline, which
compares well to the data shown in [1]. The trend of the population growth is
similar in all three cases.
We next look at the how the fractions of sensitive and resistant cells change
over time. The results are shown in Fig. 3.5. We compared simulations of our
model (3.2)–(3.4) with simulations of the model of [1] given by (3.1). The simulations
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results are plotted on top of the experimental data of [1]. A comparison between
the results produced by both models shows that the new model (3.2)–(3.4) provides
a substantially better match to the experimental data over the simulated 96 hours,
compared with the model (3.1), both in terms of the absolute error, as well as
the overall trend. We see an early inflection point in our model due to the faster
proliferation rate of the sensitive cells. Initially the growth of the sensitive cell
fraction outpaces the resistant cell fraction. After around 12 hours the resistant
cells begin to catch up. Then the transfer of resistance contributes to a rise in
the fraction of resistant cells. We significantly oversampled the data to check for
overfitting and the results were similar, which makes sense given the lack of observed
oscillations in the experiemental data.
We test the sensitivity of the model (3.2)–(3.4) to changes in four of the pa-
rameters, d, c, ε, and ξ. Fig. 3.6 shows how the overall population varies when d, c,
and ε, respectively, are changed. We ran simulations to compare how the sensitive
and resistant fractions change but these result with only negligible changes so we
focus on total cell population. Changes to d, the parameter governing the fraction
of cells in apoptosis, are shown in the top left graph in Fig. 3.6. There is a small
effect on the overall population once it has reached carrying capacity with a larger
death parameter correlating with a faster decline but the system overall does not
change much as d changes. The cellular reaction rate c amplifies the magnitude
of cells moving from quiescent stage into the cell cycle. The simulation shown in
the top right graph in Fig. 3.6 confirms that a low c value correlates with slower
growth. However, for larger values of c, the growth is mostly independent of c. The
34
















































































































































Figure 3.5: Fractions of resistant (left) and sensitive (right) cells over time. Top:
initial ratio 1:1. Middle: initial ratio 3:1. Bottom: initial ratio 7:1. Dots correspond
to the experimental data of [1]. Dashed lines are simulations with the model (3.1)
of [1]. Solid lines are simulations of (3.2)–(3.4).
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Figure 3.6: Sensitivity study of (3.2)–(3.4) for the case of an initial sensitive to
resistant ratio of 3:1. All graphs show the total cell population over time. Top
Left: varying d, the fraction of cells in apoptosis. Top Right: varying c, the cellular
reaction rate that governs the transition from quiescent to proliferative. Bottom:
varying ε, the shape parameter for β(ρ).
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parameter ε governs the shape of β(ρ), the equilibrium, or desired, amount of cells
in the cell-cycle. The bottom left graph in Fig. 3.6 demonstrates that the total
population is sensitive to changes in ε. While the sensitive and resistant fractions
remain consistent, any deviation from ε = 0 leads to a significant decrease in the
overall growth. ε = 0 implies that β(ρ) = βm, a constant. This corresponds to a
lack of dependence on density. We expect this to be the best fit as the model and
experimental data address a local phenomenon.
The parameter ξ, which governs the fraction of sensitive quiescent cells that
become temporarily resistant as they enter the cell cycle, is the final parameter we
varied. Resistant cells proliferate at a slower rate but we see that the difference is
not enough to induce change on the overall population. However, there is a shift
in the sensitive and resistant fractions, as would be expected. Fig. 3.7 shows the
population and the two fractions while Fig. 3.8 shows a zoomed on version of Fig. 3.7
to highlight the shift towards more resistance as ξ is raised. The larger ξ is, the
more cells become temporarily resistant and so the overall resistant fraction rises.
We also ran simulations in which we allowed the sensitive and resistant cells
to have the same growth parameters (i.e., a normal distribution with identical mean
and standard deviations for the cell cycle length). Without the slower proliferation
our optimized parameters have a much larger value for ξ, the fraction of sensitive
quiescent cells that become temporarily resistant. In these simulations we have
almost half of them becoming resistant (ξ = 0.4828). The results of these simulations
are shown in Fig. 3.9 (compare with Fig. 3.5 where resistant cells are assumed to grow
slower than the sensitive cells). Even in this case, our model (3.2)–(3.4) provides a
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Figure 3.7: Top Left: Fraction of sensitive cells as ξ, the fraction of sensitive qui-
escent cells that transition to temporarily resistant when in the proliferative state,
varies. Top Right: Fraction of resistant cells as ξ varies. Bottom: Total Population
as ξ varies.
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Figure 3.8: Left: A close up for the fraction of sensitive cells as ξ, the fraction of
sensitive quiescent cells that transition to temporarily resistant when in the pro-
liferative state, varies. Right: A close up for the fraction of resistant cells as ξ
varies.
better match in capturing the trend of the data compared with the model of [1].
We note that the parameters are optimized based on the available experimental
data that was collected over the first 96 hours. When simulating our model beyond
96 hours with identical growth distributions for the sensitive and the resistance cells,
the fractions of sensitive and resistant cells trend back towards their initial values.
The model (3.1) exhibits a limit dynamics in which the sensitive and resistant cells
settle towards equilibrium values albeit values that are different than the initial
distribution.
It is easy to understand the reason for this asymptotic behavior when the
growth distributions of sensitive and resistant cells are identical. In this case, we
can assume that Rp changes at a similar rate to Sp+Tp. When the carrying capacity
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is approached, β(ρ) gets increasingly small. This means that the transition rates
from quiescence to the proliferative compartment shrink. Once all the temporarily
resistant proliferating cells divide into sensitive quiescent cells, the transition rates
are too small to repopulate Tp. The overwhelming majority of cells are quiescent,
either resistant or sensitive. When temporary resistant cells make up a small fraction
of the population, the asymptotic distribution of cells reverts to the initial values.
This can all be avoided by allowing the resistant population to proliferate at a slower
rate than the sensitive cells, which is a biologically solid assumption [74].
3.4 Discussion
Mathematical models of the mechanisms of cellular growth may assist in study-
ing and understanding the emergence and evolution of MDR. The cell-to-cell trans-
fer of P-gp and its effect have not been extensively studied by the mathematical
community.
In this chapter we propose a model for the resistance transfer between cells.
Our model assumes that cells are either quiescent, proliferative, or in the apoptotic
stage. Cells in the quiescent and proliferative stages are designated either resistant
or sensitive, with an extra compartment for temporarily resistant proliferative cells.
We assume that a certain fraction of sensitive cells become temporarily resistant
due to P-gp transfer as they become proliferative and enter the cell cycle. This
model is an extension of the cancer growth model of Greene et al. [2] to which we
incorporated drug resistance.
40
















































































































































Figure 3.9: Fractions of resistant (left) and sensitive (right) cells over time assuming
identical growth parameters for the sensitive and the resistant cells. The parameters
used in this figure are given in Table 3.3. Top: initial ratio 1:1. Middle: initial ratio
3:1. Bottom: initial ratio 7:1. Dots correspond to the experimental data of [1].
Dashed lines are simulations with the model (3.1) of [1]. Solid lines are simulations
of (3.2)–(3.4).
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We fit our model to the experimental data from [1] and show that the more
detailed description of the growth dynamics in our model provides a better fit to
the experimental data than the fit that can be obtained using the original model
of [1]. We demonstrate that a better match to the experimental data is obtained
when resistant cells are allowed to grow at a different rate than the sensitive cells.
The best fit is obtained when the resistant cells grow more slowly than the sensitive
cells, which is consistent with known experimental data.
With this better fit our model could now potentially be used for studying a
similar setup under drug treatment. Given data on sensitive and resistant responses
to the action of a drug, this would be a reasonable next step.
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Chapter 4: A Reaction-Diffusion Model for the Spread of Transferred
Resistance
In this chapter we present another extension of Durán et. al [1]. Here we
incorporate a spatial component rather than a cell-cycle model. The structure of the
chapter is as follows: we begin with a simple reaction-diffusion model for resistant
and sensitive cancer cells. We then add a temporarily resistant type, mirroring the
model of chapter 3. We then look at a system with no P-glycoprotein transfer but
the inclusion of a chemotherapeutic drug. Finally we put it all together with a model
that incorporates transferred resistance alongside the mass action of the drug.
4.1 A First Model
Reaction-diffusion equations are a common type of parabolic partial differ-
ential equations. They can be applied to chemistry, biology, physics, and other
dynamic processes [75]. These equations have been used in the study of pattern
formation since Alan Turing’s seminal work on morphogenesis [76]. The change
in the concentration variable is modeled as a function of two forces, a (chemical
or otherwise) reaction along with diffusion across space. We begin with a coupled
reaction-diffusion system: a scaled Lotka-Volterra competition model with the ad-
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dition of diffusion [77]. This system with diffusion and competition is commonly
called a Fisher-KPP system (Kolmogorov, Petrovsky, and Piskunov) [78,79].
∂ u
∂ t
= Du∆u+ u(1− u− v), (4.1a)
∂ v
∂ t
= Dv∆ v + av(1− u− v). (4.1b)







model u(x, y, t) represents the density of the cancer cells sensitive to a drug, with
values between 0 and 1, while v(x, y, t) represents the density of the cancer cells
exhibiting MDR. Each diffuses at a certain rate, Du and Dv, respectively. Both
sets of cells exhibit logistic growth limited by competition for space. We let a < 1
assuming that resistant cells grow slower than sensitive cells. We will revisit this
assumption later in this chapter.
4.1.1 Numerical Methods
In order to simulate (4.1) we discretize the system using the finite difference
method. We use n for each time step and i and j for the two spatial dimensions.









We use an implicit 5-point stencil for the finite difference approximations. In











where h = ∆x. We take the sum of the four closest values at the next time step,
n+ 1, and subtract four times the value of the (i, j) component at t = n+ 1. This is
an implicit method so combined with the explicit Euler, we are using a semi-implicit
method of updating each component. This allows us to solve a linear system for
each un+1i,j and v
n+1
i,j . For each u
n+1













We set up the discretized equation for vn+1i,j in the same manner. In implement-
ing the code on Matlab we utilize sparse matrices to increase the efficiency of the
simulation. The simulations of the extensions of this model used in the upcoming
sections all use a similar discretization.
Since we are going to use this as an extension of Durán et. al [1] in the next
sections, we run a simulation assuming a 1:1 ratio of sensitive to resistant cells
equally spaced in the center of a two-dimensional domain with Dirichlet boundary
conditions (Figure 4.1). We set u = 0 and v = 0 on the boundary. Without the
presence of a drug, the competitive advantage of the sensitive cells allows them
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to quickly overtake the resistant population. What looks like a dip in sensitive
population in the center is due to the population growing faster at the edge and the
center eventually catching up. The plots show the respective densities after 10, 50,
and 100 hours. The parameters used throughout the simulations are described in
Section 4.2.1.
When we extend the simulations to two months, we see that the sensitive cells
represent over 90% of the tumor in Figure 4.2, as expected. In this simple case,
the only distinction between the two populations is the slower growth rate of the
resistant cells, making it clear that the advantage lies with the sensitive cells.
Simulations for populations with 3:1 and 7:1 initial ratios exhibit similar, if
exaggerated, characteristics. Without any external forces on this system, the re-
sistant cells cannot overcome the sensitive cells and, while the tumor will grow to
capacity, the sensitive cells will dominate.
4.1.2 Fisher’s Equation
When we make two simplifying assumptions, namely that Du = Dv = D, and
a = 1, then we can rewrite the system (4.1) as follows:
∂ u
∂ t
= D∆u+ u(1− u− v), (4.5a)
∂ v
∂ t
= D∆ v + v(1− u− v). (4.5b)






































































































































Figure 4.1: Simulation of (4.1). Densities of sensitive (left) and resistant (right)















































Figure 4.2: Simulation of (4.1). Densities of sensitive (left) and resistant (right)
cells after two months. Initial 1:1 ratio.
∂µ
∂ t
= D∆µ+ µ(1− µ). (4.6)
Equation (4.6) is the classic Fisher equation, from the 1937 paper on the spread
of a certain allele [78]. There are two equilibrium states, µ = 0, and µ = 1, and in
between traveling wave solutions can exist. We can see these in Figure 4.3 as the



































































Figure 4.3: Simulation of the Fisher equation (4.6). Overall tumor density is shown




As discussed in Chapters 2 & 3, the overabundance of P-glycoprotein pumps
leads to MDR. We understand that resistant cells can transfer P-gp pumps to nearby
sensitive cells. We apply the transfer of resistance terms of [1] to (4.1) to incorporate
a third equation for those temporarily resistant cells.
∂ u
∂ t
= Du∆u+ u(1− u− v − w)− kuuv + kww, (4.7a)
∂ v
∂ t
= Dv∆ v + avv(1− u− v − w), (4.7b)
∂ w
∂ t
= Dw∆w + aww(1− u− v − w) + kuuv − kww. (4.7c)
Here, w(x, y, t) represents temporarily resistant cells. The resistant cells trans-
fer a small amount of P-gp pumps to nearby sensitive cells, allowing for a short-term
change in the resistant phenotype. After a specified amount of time, controlled by
kw, the temporarily resistant cell turns back into a sensitive cell.
4.2.1 Simulations of The Transferred Resistance Model (4.7)
As in Chapter 3, we optimized parameters using Matlab’s nonlinear least
squares function. We fit the solution of (4.7) to the experimental data of [1]. To deal
with the inherent scarcity of data points and concerns about overfitting we synthe-
sized extra points using linear interpolation to confirm our results. Since we do not
assume any phenotypic difference between resistant and temporarily resistant cells,
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we force av = aw in all simulations. The full set of parameters with their ranges is
given in Table 4.1. The optimal values used in the simulations are given in Table
4.2.
The results for the parameter optimization are shown in Figures 4.4 and 4.5.
The top plot in Figure 4.4 shows the percentage of sensitive cells in (4.7) over 100
hours against the experimental data. For comparison, the bottom plot shows the
simulations of (3.2)-(3.4) and of [1] against the same experimental data. Whereas
(3.2)-(3.4), while originally a great improvement, had a small jump in percentage
followed by a linear decline, (4.7) follows the data much more closely. We can
see similar effects in Figure 4.5 for resistant cells, which in all cases include both
permanently and temporarily resistant cells. Using these parameters we now can
look at further growth dynamics.
We see the growth of the system over those same 100 hours in Figure 4.6. We
start with an equal amount of sensitive and resistant cells spaced in a small grid
in the center of our domain. We set no initial temporarily resistant cells and keep
u = 0, v = 0, w = 0 as the Dirichlet boundary condition. In the top row of Figure
(4.6) we see an initial depletion of sensitive cells due to the transfer of P-gp from the
nearby resistant cells. Meanwhile on the edge of the initial population the sensitive
cells grow faster than the resistant cells due to their competitive advantage. After
100 hours we see that the relative sizes of each population are almost uniformly
dispersed throughout our domain. The optimized transfer terms were ku = 0.1150
and kw = 0.0757, agreeing with common understanding that the transfer of P-gp
is not an overwhelming aspect of the system. Despite the existence of temporarily
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Table 4.1: Parameter Values & Descriptions
Parameter Range Description
tend [0,1460] (hours) Length of Time Interval
Nz [10, 1000] Length of one side of square domain
dt [0.1,10] (hours) Length of discretized time step
dz [0.1,10] Length of spatial step
Du [0.05,5] Diffusion coefficient for sensitive cells
Dv [0.05,5] Diffusion coefficient for resistant cells
Dw [0.05,5] Diffusion coefficient for temporarily resistant cells
Dc [0.05,∞) Diffusion coefficient for the drug
ε [0,∞) Scaling parameter for drug diffusion
av [0.5, 0.85] Growth parameter for resistant cells
aw [0.5, 0.85] Growth parameter for temporarily resistant cells
du [0.8, 1] Death parameter of sensitive cells due to drug
dv [0.1, 0.5] Death parameter of resistant cells due to drug
dw [0.1, 0.5] Death parameter of temporarily resistant cells due to drug
γ [0,1] Inherent decay rate of drug
λu [0,1] Drug uptake parameter for sensitive cells
λv [0,1] Drug uptake parameter for resistant cells
λw [0,1] Drug uptake parameter for temporarily resistant cells
ku [0.01, 0.2] P-gp transfer parameter for sensitive and resistant cell interaction
kw [0.01, 0.2] Reversion parameter for temporarily resistant back to sensitive
51















































Figure 4.4: Fractions of sensitive cells over time assuming a 1:1 initial ratio. Dots
correspond to the experimental data of [1]. Top: simulation of the model (4.1).
Bottom: a dashed line simulation of the model (3.1) of [1] and a solid line simulation
of (3.2)-(3.4).
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Figure 4.5: Fractions of resistant cells over time assuming a 1:1 initial ratio. Dots
correspond to the experimental data of [1]. Top: simulation of the model (4.1).
Bottom: a dashed line simulation of the model (3.1) of [1] and a solid line simulation
of (3.2)-(3.4).
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Table 4.2: Parameters values used in simulations with Dv 6= Dw.
Parameter Nz dt dz Du Dv Dw Dc
Value 101 1 0.5 0.05 0.0592 0.0585 1
Parameter ε av aw du dv dw γ
Value 0.5 0.85 0.85 0.85 0.2 0.2 0.4
Parameter λu λv λw ku kw
Value 0.5 0.05 0.05 0.1150 0.0757
resistant cells, the dominant growth term of the sensitive cells still allows them
to win over the resistant cells. This is further seen in Figure 4.7, which shows
the system after two months. As with the case with no temporary resistance, the
supermajority of cells are sensitive.
We showed that in the case of no P-gp transfer the sensitive cells dominate and
now, with fully optimized parameters capturing the experimental data, we see that
the transfer of resistance cannot affect the system enough to overcome the inherent
competitive advantage of the sensitive cells. In the next section we incorporate a
drug in order to study the effects of chemotherapy on sensitive cells, resistant cells,








































































































































































































Figure 4.6: Simulation of (4.7) over 100 hours. Densities of sensitive (left), resistant
(middle), and temporarily resistant (right) cells are plotted over time. Top: t=10



































































Figure 4.7: Simulation of (4.7) over two months. Densities of sensitive (left), resis-
tant (middle), and temporarily resistant (right) cells are plotted over time.
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4.3 Drug Treatment
We now take a sideways step and remove the temporarily resistant cells in
order to study how a cytotoxic drug affects the system with solely sensitive and
resistant cells. We allow the drug to affect both sensitive and resistant cells, as the




= Du∆u+ u(1− u− v)− duuc, (4.8a)
∂ v
∂ t
= Dv∆ v + av(1− u− v)− dvvc, (4.8b)
∂ c
∂ t
= ∇ · (D(v)∇ c)− c(γ + λuu+ λvv). (4.8c)
The drug, c, shrinks both the sensitive and resistant cell populations through
a mass action term, where du >> dv to represent the inherent resistance in v. The
diffusion of the drug is affected by the term D(v). The overexpression of P-gp in
the resistant cells expels the drug so we will have ∂ D
∂ v
> 0, signifying an increase in
diffusion when the drug is in the presence of resistant cells. In this section we set
D(u, v) = 1 + ε v2 for a small ε > 0. The final term represents the accumulation of
decay and uptake loss of the drug. γ < 1 is the fraction of the drug that decays
at each time step. λu and λv are parameters that mediate the amount of drug that
is ingested by sensitive and resistant cells, respectively. Since the overexpression of
P-gp pumps allows resistant cells to push the drug back out, λv < λu.
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4.3.1 Simulations of The Drug Treatment Model (4.8)
We begin with two simulations of the system (4.8) under constant infusion of
the drug. c = 5 is the continuous boundary condition in Figures 4.8 & 4.9. Both
figures show the development of sensitive and resistant cells over a time scale of
500 hours. Now that we are using the optimal parameters we study the effects of
a drug past several days. We see that the number of sensitive cells is dramatically
reduced, understandably so with du = 0.85 and dv = 0.2. We do not allow resistant
cells to be completely resistant, allowing some of the drug to get past the volume
of P-gp pumps. It is clear that continuing this further will result in the resistant
cells completely taking over, rendering chemotherapy ineffective. Figure 4.8 shows
the results of initial 1:1 ratio in the same location in the center of the domain, while
Figure 4.9 shows the dynamics if the tumor were split into two distinct regions, one
filled with sensitive cells and the other solely resistant. The results after 500 hours
are almost indistinguishable, suggesting the physical makeup of the tumor does not
play a role in the overtaking by the resistant cells.
Figure 4.10 shows the same development of the system but under a significantly
smaller drug dose. In this case c = 0.1 on the boundary and so the effects of the drug
are notably slowed. The middle two plots, showing the system after 100 hours, or
approximately 3 days, demonstrates that the competitive advantage of the sensitive
cells is still active in the middle region. The drug has not yet managed to penetrate
deep into the tumor and so there are more sensitive cells there. Meanwhile near the






































































































































Figure 4.8: Simulation of (4.8). Initial centered 1:1 ratio. Densities of sensitive (left)
and resistant (right) cells are shown over time under constant drug infusion (c=5).






































































































































Figure 4.9: Simulation of (4.8). Initial 1:1 ratio, separated into distinct sections
of only sensitive and only resistant cells. Densities of sensitive (left) and resistant
(right) cells are shown over time under constant drug infusion (c=5). Top: t=20
hours. Middle: t=100 hours. Bottom: t=500 hours.
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cells are growing more rapidly.
The most important result is shown in Figures 4.11 and 4.12. Under uniform
constant infusion of a drug on the boundary, we are unable to prevent the tumor
from growing. As seen in Figures 4.8 and 4.9, constant infusion eradicates the
sensitive cells and leaves a resistant tumor growing with little inhibition. Even in
the case of a small dose, the resistant population will eventually take over and the
therapy will be unsuccessful.
4.4 The Full Model
We combine all ingredients together in our full model. This model incorporates
the transfer of P-gp pumps as well as a chemotherapeutic agent. All populations:
sensitive (4.9a), resistant (4.9b, and temporarily resistant (4.9c), have now has a
mass action death term due to interaction with the drug. A new uptake term
λww is included in the equation for the drug. The diffusion coefficient D(v) is now
D(v, w), with ∂ D
∂ v
> 0 and ∂ D
∂ w
> 0, and we take it to be D(v, w) = 1 + ε(v + w)2.
The resulting system is:
∂ u
∂ t
= Du∆u+ u(1− u− v − w)− kuuv + kww − duuc, (4.9a)
∂ v
∂ t
= Dv∆ v + avv(1− u− v − w)− dvvc, (4.9b)
∂ w
∂ t
= Dw∆w + aww(1− u− v − w) + kuuv − kww − dwwc, (4.9c)
∂ c
∂ t






































































































































Figure 4.10: Simulation of (4.8). Densities of sensitive (left) and resistant (right)
cells are shown over time under constant drug infusion (c=0.1). Top: t=20 hours.




































































Figure 4.11: Simulation of (4.8). Overall tumor density is shown over a period of
100 hours under constant drug infusion (c=5). Left: t=20 hours. Middle: t=100



































































Figure 4.12: Simulation of (4.8). Overall tumor density is shown over a period of
100 hours under constant drug infusion (c=5). Left: t=20 hours. Middle: t=100
hours. Right: t=500 hours.
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We use the complete model to study the effects of varying therapy protocols.
We run simulations for constant infusion, intermittent infusions, and a combination
of the two. We also find drug protocols that minimize overall tumor size and also
total density of resistant cells.
4.4.1 Constant Infusion
We previously saw that a constant infusion of the drug would force the sensitive
population to contract until the system is dominated by resistant cells. Since the
only change is a new mechanism (transfer of resistance) that diminishes the sensitive
cell population, it makes sense that the full model will induce similar dynamics. In
this case not only is the drug coming in from the boundary harming the sensitive cells
but so does the interaction with the initial resistant cells in the center. This is shown
in Figure 4.13, with c = 5 on the boundary. The temporarily resistant cells emerge in
the center of the domain, where there is an overlap between resistant and sensitive
cells. This population continues to grow until the population of sensitive cells is
so small that there are not enough cells left to sustain the size of the temporarily
resistant population. Figure 4.14 shows the same time frame but with a smaller
dose (c = 0.1) along the boundary. Again, the resistant cell population grows faster
near the boundary while the sensitive population decreases in the center due to the
transfer of P-gp pumps. Both cases show what we have previously seen: a constant








































































































































































































Figure 4.13: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under









































































































































































































Figure 4.14: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under




Since constant drug infusion will eliminate all sensitive cells and lead to a
drug resistant tumor, we consider other treatment protocols. We need to maintain
a robust sensitive cell population since that is the only mechanism for controlling
the resistant population. We study this scenario in a series of simulations. In each
simulation we administer the drug for 8 hours at a time and then turn it off for
varying lengths of time. Figures 4.15 and 4.16 show the results over 500 hours of
implementing the treatment every 24 hours. In this case it is 8 hours on and 16 hours
off. Figure 4.15 is for the higher dose, c = 5, while Figure 4.16 shows the effects
of the lower does, c = 0.1. We see in Figure 4.15 that we still have a significant
upswell in the resistant population and a resistant cell-dominated tumor develops
within days. The smaller dose, on the other hand, allows the sensitive population
to control the growth of resistant cells.
Figures 4.17 & 4.18 show the same two scenarios but with the drug adminis-
tered once every 96 hours rather than once a day. We see again that the lower dose
allows the sensitive cells to sustain themselves. In between doses, the sensitive cells
grow along the boundary where resistant cells are at their lowest levels.
With the simulations as a guide we consider optimizing therapy protocols to









































































































































































































Figure 4.15: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under
on/off therapy (c=5). The drug is pumped for 8 hours at a time every 24 hours.








































































































































































































Figure 4.16: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under
on/off therapy (c=0.1). The drug is pumped for 8 hours at a time every 24 hours.








































































































































































































Figure 4.17: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under
on/off therapy (c=5). The drug is pumped for 8 hours at a time every 96 hours.








































































































































































































Figure 4.18: Simulation of (4.9) with initial 1:1 ratio. Densities of sensitive (left),
resistant (middle), and temporarily resistant (right) cells are shown over time under
on/off therapy (c=0.1). The drug is pumped for 8 hours at a time every 96 hours.
Top: t=20 hours. Middle: t=100 hours. Bottom: t=500 hours.
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4.4.3 Optimal Therapies
In order to find an optimal treatment plan we first consider minimizing the




(um + vm + wm) dt, (4.10)
where J(u, v, w, c, t) is the total volume of the tumor over the entire simulation,
and m is either 1 or 2, for linear or quadratic control. We also consider K =
u(tend) + v(tend) + w(tend) for a measure of the size of the tumor at the end of the
simulation. Since we do not need to look at every single possible treatment plan, we
pick 11 protocols, ranging from constant infusion to infusion once every three weeks.
We also allow for 8 different sizes of the dose, ranging from no drug, c=0, to c=100.
In finding the optimal treatment plan for these options we see that the treatment
that minimizes the total volume of the tumor J is the same as the treatment that
minimizes the final volume of the tumor K. Unfortunately, this optimal result is
constant infusion with the highest dose possible. We have already seen that constant
infusion leads to a sharp increase in the proportion of resistant cells and allows them
to eventually take over and dominate.
With that result we then look at what treatment plan will minimize the amount
of resistant cells in the tumor. As long as we can keep the resistant cell population
low then there is an opportunity for chemotherapy to work. We optimize over the
same set and the result is the opposite approach from the one we found above. As
the previous simulations suggested, the lower the drug dose, the better the chance
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that the sensitive cells would control the resistant population. We find that the
way to minimize resistant cells is, in fact, to deliver no drug at all. This makes
sense in our model since, with dv and dw so small, the one truly effective mechanism
for keeping the resistant cell population down is the competitive advantage of the
sensitive cells. Any drug input decreases their number significantly and so the
optimal way to control the resistant population is to leave the sensitive population
uninhibited, meaning no chemotherapy at all.
4.5 Discussion
In this chapter we presented a model of P-gp transfer in a two-dimensional
space. We began with a simple reaction-diffusion system and incorporated the trans-
fer of resistance as well as chemotherapeutic agent. When a < 1, the competitive
advantage allows the sensitive cells allows them to grow at the expense of the re-
sistant population. While the spread of temporary resistance through the transfer
of P-gp pumps does not have a strong enough effect to overcome this trend on its
own, the inclusion of a drug may result with a significant growth of the resistant
population.
In looking for optimal treatment protocols we run into a conundrum. The
resistant population is minimized when no drug is applied, yet this leads to the
maximum tumor size. The tumor size is minimized when treated with a constant
infusion of a large dose, yet this leads to an almost fully resistant tumor. Higher
amounts of drug result with smaller tumors. Unfortunately, this correlates with the
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emergence of more resistant tumors. Within the confines of this model we cannot
achieve a treatment protocol that slows down tumor growth while also assuring that
tumor does not become resistant over time.
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Chapter 5: A Model for Drug Resistance as a Continuous Variable
5.1 Introduction
In this chapter we extend the work by Pasquier et. al. [44], and the latest
paper, Magal et. al. [3], from the same group. These studies treat resistance as a
continuous variable. Magal et. al. [3] consider a PDE model with a Boltzmann type
integral describing the transfer of P-gp under multiple transfer rules:
∂ u(t, x)
∂ t
= 2τ [T (u(t, ·))(x)− u(t, x)], for x ∈ R (5.1a)
u(0, ·) = u0 ∈ L1+(R). (5.1b)
Here u(t, x) is the density of cancer cells at time t with resistance level x, defined













R π1(p)u(x+ f1(p)p)u(x− (1− f1(p)p)dp
+
∫
R π2(p)u(x+ f2(p)p)u(x− (1− f2(p)p)dp.
(5.3)
The model exhibits an intrinsic death term along with T , a growth rate due
to a transfer of P-gp between individual cells. The probability that a pair of cells
74
Figure 5.1: The possible transfers under each transfer efficiency f1 and f2. y
old
and zold are the transferrable quantities of P-gp expression. yold > zold in all four
scenarios. Figure adapted from [3].
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is involved in a transfer is chosen randomly and is independent of resistance levels.
τ represents the transfer rate where the time between transfers is modeled by an
exponential law with mean τ−1. f(p) is the transfer efficiency and each cell has an
intrinsic p value and those with higher p values lose f(p) times the difference of the
p values of the two cells involved in the transfer. In [44] only one transfer efficiency
function f(p) is used, while in [3] two different efficiency functions, f1 and f2, are










[1− (f1 + f2)(p)]
. (5.4)
Figure 5.1 shows the four different types of transfer functions with efficiencies
f1(p) and f2(p). There are four possible transfers resulting in resistance level y
new
and four corresponding transfers resulting in znew. The new resistance level ynew
can come from yold giving away f1(p)p or f2(p)p of its resistance level to lower it
to ynew as seen in Figure 5.1(a) and 5.1(b). Alternately, ynew can come from zold
gaining either f1(p)p or f2(p)p to increase its resistance level.
We extend this idea to include cellular proliferation as well as a new spatial
dimension. In Section 5.2 we introduce our model with a single transfer rule and
discuss simulations and results. In Section 5.3 we add a cytotoxic drug and study its
effect on the distribution of resistance levels. In Section 5.4 we extend the work to
include two transfer rules f1 and f2. Concluding remarks are provided in Section 5.5.
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5.2 The First Model
We incorporate the idea of continuous resistance into a reaction-diffusion
model. We develop a model that includes the transfer of resistance alongside dif-
fusion and density inhibited population growth. We denote p as the continuous
resistance variable, and x as the 2-dimensional space variable. Each cell occupies a
location (i, j) in the 2-d domain. We keep the assumptions on P-gp transfer from [3].
The addition in the transfer term is the stipulation that cells must be within a small
neighborhood of each other to be able to transfer P-gp. The model is shown below:
∂u(x, p, t)
∂t
= D∆u+ au(1− u) + 2τ
[ ∫
B(x)
T (u)(p) dx− u
]
(5.5a)
u(·, ·, 0) = u0 ∈ L1+(R). (5.5b)
We set Dirichlet boundary conditions with u(0, ·, ·) = u(X, ·, ·) = 0. D is the
diffusion coefficient and a controls the speed of cellular growth. 2τ
∫
B(x) T (u)(p) dx
describes all the cells that have resistance level p after a successful transfer. −2τu is
the flux representing cells that had resistance level p but have successfully transferred
P-gp. τ is the rate of P-gp transfer per unit of time.
We develop a transfer term with a single transfer rule based on [80]. We inte-
grate over a small neighborhood allowing the cancer cells to only transfer resistance
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Here, f(p) ≡ f is the transfer efficiency, defined as a constant. We incorporate the
idea from [3] that interaction between cells with a large and a small difference in
resistance level should not yield large changes. We define f as follows:
f(p1 − p2) =

f if (p1 − p2) ∈ (δmin, δmax),
εf f otherwise.
(5.8)
Here, f is a function of the difference in resistance levels p1 and p2. If the resistance
levels of the two interacting cells are within a threshold then the transfer efficiency
is f . If they are too small or too large, the transfer efficiency becomes εf f , for a
small εf > 0. The amount of P-gp transferred is determined by multiplying the
densities of the two transferring entities. The explanation for the terms inside the
integrals follows below.
Figure 5.2 shows the four possible scenarios in which a cell results in resistance
level p after a transfer. Assume two cells have resistance levels p1 and p2. If p1 ≤ p2
then their interaction will lead to p2 transferring a certain amount of resistance
to p1. There are two ways that can end in a cell with resistance level p. (i): if
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Figure 5.2: The four possible transfers resulting in a cell having P-gp expression level
p with one predecessor having P-gp expression level p2. Figure adapted from [80].
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p = p1 + f ∗ (p2−p1) then we solve for p1 so p1 = p−fp21−f . (ii): if p = p2− f ∗ (p2−p1)
then we solve for p1 so p1 =
p−(1−f)p2
f
. Now, if p2 ≤ p1 we have the two scenarios
but with the two cells in the opposite position: (i): if p = p1 − f ∗ (p1 − p2) then
we solve for p1 so p1 =
p−fp2




. Despite having four scenarios there is overlap so we only have
two distinct values for p1 in terms of the desired resistance level p and any other
resistance level p2. This gives us the two integral terms in (5.7).
The continuous model has two qualitative changes from the model in Chap-
ter 4. In this setting we do not consider temporary levels of resistance. Each transfer
is considered a permanent change. We also assume that resistance cells lose a por-
tion of their resistance during each transfer, unlike (4.9). In Chapter 4 P-gp transfer
is assumed to affect only sensitive cells.
5.2.1 Numerical Methods
We discretize our model (5.5)-(5.8) in a similar manner to section 4.1.1. We
use a semi-explicit method of updating each component, with explicit Euler dis-
cretization in time, and our implicit 5-point stencil in space. We repeat the specifics
below, with the addition of an extra dimension p.
We use n for each time step and i and j for the two spatial dimensions. The









We use an implicit 5-point stencil for the finite difference approximations. In











where h = ∆x. For each un+1i,j,p , we have:
un+1i,j,p ≈ Duλ (un+1i+1,j,p + un+1i−1,j,p + un+1i,j+1,p + un+1i,j−1,p − 4un+1i,j,p)
+auni,j,p(1− uni,j,p)k + 2τ(F − uni,j,p)k + uni,j,p,
(5.11)
with F defined in (5.12) and λ = k
h2
. We solve the linear system (5.11) in Matlab
utilizing the efficiency of sparse matrices. The simulations of the extensions of this
model used in the upcoming sections all use a similar discretization.
Our spatial grid is coarse enough that we allow cancer cells to transfer P-gp
to others within the same grid space. If both cells are of the form u(i, j, :) they have
an interaction and transfer the protein between each other. F is the discretization





















ui,j,p∆ p ∗ h2
(5.12)
The parameters used in the simulations are shown in Table 5.1. We use pa-
rameter values from the PDE model in Chapter 4 along with τ and f from [3].
Table 5.2 shows the values used in our simulations.
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Table 5.1: Parameter Values & Descriptions
Parameter Range Description Reference
tend [0,1460] (hours) Length of Time Interval Table 4.1
Nz [10, 1000] Length of one side of square domain Table 4.1
dt [0.1,10] (hours) Length of discretized time step Table 4.1
dz [0.1,10] Length of spatial step Table 4.1
D [0.05,5] Diffusion coefficient for cancer cells Table 4.1
a [0.5, 5] Growth parameter for cancer cells Table 4.1
τ [0,1] Transfer rate of P-gp between cancer cells [3]
f [0,1] Efficiency of transfer of P-gp expression [3]
Table 5.2: Parameters values used in simulations of (5.5)-(5.7) and (5.13).
Parameter Nz Nm dt dz D Dc
Value 100 100 1 0.5 0.05 1
Parameter τ f εf ε a γ
Value 0.9 0.1 0.01 0.5 0.85 0.4
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5.2.2 Simulations
We begin by studying the overall growth of the tumor. Since there is no drug
and the transfer of resistance should not affect full tumor growth we expect the


































































Figure 5.3: Simulation of (5.5)-(5.7). Overall tumor density is shown over a period
of 100 hours. Left: t=10 hours. Middle: t=50 hours. Right: t=100 hours.
We see in Figure 5.3 that the tumor grows as expected. We next study the
changes in resistance levels. [3] showed that when starting with high amounts of
very sensitive and very resistant cells, over a period of 7 days the transfers led to
a much more even distribution. To study this setting, we begin with a prescribed
initial density for resistance levels between [0, 0.1] and [0.9, 1]. We let the density for
the population in between be one half of the initial density on each end. Figure 5.4
shows our initial result for a simulation of 100 hours.
We see that very little transfer has taken place. We address this by raising
the speed of transfer and simulating for a full week. We see in Figure 5.5 a similarly
high level of volatility that was also found in [3]. We also see that after 7 days
the resistance level has spread and become more even. This becomes more obvious
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Figure 5.4: Simulation of (5.5)-(5.7) over 100 hours. Density of tumor cells at each
level of P-gp expression.
when we zoom out of the far right figure in Figure 5.5, as shown in Figure 5.6.





















































Figure 5.5: Simulation of (5.5)-(5.7). Density of tumor cells at each level of P-gp
expression with raised speed of transfer. Left: t=24 hours. Middle: t=96 hours.
Right: t=168 hours.
5.3 Incorporating a Drug
We now proceed by including a cytotoxic drug term. We postulate that the
drug does not affect the transfer of P-gp so T (u)(p) and T̂ (u)(p) remain as in (5.6)
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Figure 5.6: Simulation of (5.5)-(5.7) over 168 hours. Density of tumor cells at each
level of P-gp expression. Resistance is nearly uniformly distributed in this range.
and (5.7). Our new system is written as:
∂u(p, x, t)
∂t
= D∆u+ a(p)u(1− u) + 2τ
[ ∫
B(x)





= ∇ · (Dc(u)∇ c)− c(γ + λu(p)u). (5.13b)
We now set a = a(p) and allow the growth rate of sensitive cells to be
marginally faster than those of resistant cells by forcing ∂ a
∂ p
< 0. The drug c(x, t) has
a similar setup to (4.8c): It has a natural decay rate γ and its uptake is described
by a function λu(p), allowing for the cells with lower resistance level to absorb more
of the drug. The presence of cells with high expressions of P-gp will, as in (4.8c),
expel the drug making diffusion slightly faster, thus ∂ Dc
∂ p
> 0. The new term for
u(p, x, t) is −d(p)cu, a mass action death term due to interaction with the drug.
We define d(p) such that ∂ d
∂ p
< 0 so that cells with higher resistance level are less
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affected by the drug. We set d(p) > 0,∀p, since even high levels of P-gp expression
don’t necessarily lead to full MDR.
5.3.1 Simulations of The Drug Treatment Model (5.13)
For each expressed resistance level p we define a(p),d(p), and λu(p) as follows:
a(p) = 0.85 + 0.15(1− p), (5.14a)
d(p) = 0.2 + 0.6(1− p), (5.14b)
λu(p) = 0.05 + 0.45(1− p). (5.14c)
Both (5.14a) and (5.14b) are extensions of the values of parameters in (4.8). Maxi-
mal resistance corresponds to a death term of d = 0.2 and minimal resistance with
d = 0.8. As in (4.8), the minimal growth term is a = 0.85 and fully sensitive cells
exhibit growth with a = 1. We define Dc(u) = 1 + ε u for cells with resistance level
0.5 or higher. Dc(u) = Dc = 1 for interaction with cells with resistance level lower
than 0.5.
We begin by considering the results of the new definition of a(p) when no drug
is present. We use the same initial condition as in Section 5.2.2: a prescribed initial
amount of cells with P-gp expression between [0, 0.1] and [0.9, 1] and keep c = 0
throughout. We see in Figure 5.7 (left) that the tumor grows to its carrying capacity.
More interestingly, Figure 5.7 (right) confirms the dominance of the sensitive cells.
Figure 5.8 shows the results of simulations with varying intensities of a constant
drug infusion. The figures on the left show the overall tumor size while the figures









































Figure 5.7: Simulation of (5.13) over 100 hours. Left: Overall tumor density. Right:
Density of tumor cells at each level of P-gp expression.
of drug is increased, the size of the resistant population grows. The competitive
advantage of the cells with less P-gp expression turns out to be strong enough to
allow those with the lowest resistance levels to continue to grow despite the presence
of the drug. We see this clearer in Figure 5.9 with the spatial layout of the most
sensitive and most resistant cells. The left figure shows that the most sensitive cells
(p = 0.01) are still able to grow near the center of the tumor, while the right figure
shows that the most resistant cells (p = 0.99) are growing closer to the boundary.
If we allow our initial condition to be an equal amount of cells with each
resistance level then we can study the effect of a constant infusion. As seen in
Chapter 4, constant infusion should lead to high resistance levels. Figures 5.10
and 5.11 show results of simulations with equal amounts of all resistance levels.
Figure 5.10 shows the overall tumor size alongside the distribution along resistance
levels. Figure 5.10 (right) is reminiscent of the results in [59], where a constant
cytotoxic agent leads to a distribution approaching a delta function centered close












































































































Figure 5.8: Simulation of (5.13) over 100 hours with constant drug doses and high
initial values of very resistant and very sensitive cells. Left: Overall tumor density.














































Figure 5.9: Simulation of (5.13) over 100 hours with constant drug dose c=50. Left:
Density of tumor cells with resistance level p = 0.01. Right: Density of tumor cells







































Figure 5.10: Simulation of (5.13) over 100 hours with constant drug dose c=50 and
equal initial amounts of every resistance level. Left: Overall tumor density. Right:












































Figure 5.11: Simulation of (5.13) over 100 hours with constant drug dose c=50 and
equal initial amounts of every resistance level. Left: Density of tumor cells with
resistance level p = 0.01. Right: Density of tumor cells with resistance level 0.99.
is still allowing for some growth and that is explained further in Figure 5.11, where
we see the distribution of the most sensitive cells in the domain. The drug does not
have as much effect in the center of the tumor where the sensitive cells may continue
to grow. The most resistant cells cannot compete with the sensitive cells but they
grow near the boundary where the most sensitive cells have all been killed by the
drug.
We are interested in the most effective therapy for eradicating, or at least
controlling, the tumor. In the following section we explore treatment protocols and
find the optimal solutions.
5.3.2 Optimal Therapies
As in Section 4.4.3, we study treatment protocols and objectives. Recall-













u(i, j, p), the total amount of cancer cells in our domain at each time
step.
As in Section 4.4.3 we do not need to optimize over every possible drug treat-
ment protocol. Instead, we optimize over the same set of reasonable drug doses
and time frames. We allow for constant infusion as well as on/off infusion with 8
hours on delivered every 12 hours as well as every 24, 36, and up to one month.
We use Matlab to find not only the minimum J but also what protocol minimizes
the tumor size at the end of the simulation, u(:, :, tend). In addition, we also use the







This functional measures not only the overall tumor size but also the total
amount of drug. We do not include healthy cells in this study but it is known that
large doses of chemotherapy have unwanted negative effects on healthy cells so we
want to minimize not only the size of the tumor but also the total amount of drugs
administered.
We achieve a similar result as in Section 4.4.3: The best way to control the
tumor size under the effects of a cytotoxic drug is either to administer a maximal
continuous dose or to administer no drug at all. Administration of no drug allows
the more sensitive cells to exhibit a control over the more resistant cells will keep
the resistant cells from taking over. If large amounts of the drug are infused then
the resistant cells will take over and then the drug is unable to stop the tumor from
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growing.
Once again, we showed that in a spatial model exhibiting heterogeneity in
P-gp expression levels we cannot achieve a positive result as a function of treatment
with a cytotoxic agent alone. Changing from a discrete model of P-gp expression to
a continuous variable does not change the final outcome.
5.4 Extension to Two Transfer Rules
We conclude with a brief study of multiple transfer rules. We now incorporate
two different types of P-gp transfer (as in [3]). In this case our equation for u(p, x, t)
is still (5.5) but we now allow for f = f1 or f = f2. Following [3], we keep the
































5.4.1 Simulations of the Two Transfer Rule Model (5.17)
Table 5.3 shows the parameters used in simulations with the new transfer
rule (5.17). We set f1 = 0.48 and f2 = 0.07. These parameter values come from [3]
and we run simulations with them to see if they result in a qualitative difference in
our model.
Figure 5.12 shows the result of our first simulation. We use a(p) = a, a
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Table 5.3: Parameters values used in simulations of (5.5), (5.6), and (5.17) with two
transfer efficiency rates.
Parameter Nz Nm dt dz D Dc
Value 100 100 1 0.5 0.05 1
Parameter τ f1 f2 εf ε a γ






































Figure 5.12: Simulation of (5.5), (5.6), and (5.17) over 100 hours with high initial
amounts of very sensitive and very resistant cells. Left: Overall tumor density.
Right: Density of tumor cells at each level of P-gp expression.
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constant. Both figures closely resemble Figure 5.4. There is a slight difference
around resistance levels 0.1, 0.5, and 0.9, but the overall pattern is almost identical.
Figure 5.13 shows the same simulation but with a(p) = 0.85 + 0.15(1 − p). Again
we see a very similar result to Figure 5.7. It is a smoother curve but the qualitative
behavior remains the same.
We conclude that the model with a single transfer rule is sufficient for studying







































Figure 5.13: Simulation of (5.5), (5.6), and (5.17) over 100 hours with equal initial
amounts of every resistance level. Left: Overall tumor density. Right: Density of
tumor cells at each level of P-gp expression.
5.5 Discussion
In Chapter 5 we integrated our approach from Chapter 4 with the work of
Magal, Pasquier, et. al [3, 44]. Using a continuous variable for P-gp expression, we
wrote a PDE model with a Boltzmann type integral describing transfer of resistance
levels. We simulated and analyzed our output to compare it to the previous results.
Without data to optimize parameters we used a combination of already optimized
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parameters from Chapter 4 alongside given values for new parameters. We showed
that our model can capture the qualitative behavior shown previously. We briefly
considered the role of multiple transfer rules. Our simulations showed almost no
changes compared with a single rule.
We extended this model to include a cytotoxic drug that acts on the tumor
cells through a mass action term. We showed that constant infusion leads to a
marked increase in resistant cells, and that a cytotoxic agent alone cannot control
the overall tumor growth. Future work will include the addition of combination




Cancer is the second leading cause of death in the United States, with over 1.5
million new cases each year [4]. The probability of diagnosis with any invasive cancer
is right around 40% [4]. Detection, treatments, and therapies are all continuing to
improve and several cancers have high 5-year survival rates when found early enough.
Resistance to anti-cancer drugs continues to be an important obstacle to over-
come. There are several genetic factors that lead to drug resistance along with
natural selection as drugs are administered. P-glycoprotein is an ABC transporter
shown to confer resistance to chemotherapy [40–43]. Its overexpression can lead to
resistance levels one hundred times higher than normal tumor cells [46].
Applied mathematicians have not widely studied the transfer of P-gp. The
purpose of this dissertation was to research the current mathematical models of
P-gp and provide novel ideas to extend this field. In this dissertation we presented
three new mathematical models of the transfer of the protein pump P-Glycoprotein
and its effect on drug resistance.
Our first model provided an extension of the ODE models of [1]. In [1] the
authors wrote an system of ordinary differential equations describing the changes
in sensitive tumor cells, resistant tumor cells, and temporarily resistant tumor cells.
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They incorporated temporary resistance in their model by allowing sensitive cells
to become temporarily resistant after interaction with resistant cells. Those tem-
porarily resistant cells then stay in that phenotype for a prescribed amount of time
before they turn back into sensitive cells. This representation is driven by the fact
that this high P-gp level is a phenotypic and not genotypic change, thereby meaning
that after a few generations the progeny will be back to fully sensitive.
Our approach was to consider a cell-cycle model. We modeled three compart-
ments: quiescent, proliferating, and apoptotic. We allowed cells in the quiescent
stage to be either resistant or sensitive and modeled that switch to temporary resis-
tance during the shift from quiescence to proliferative stage. The proliferating cells
were broken up into three types: sensitive, resistant, and fully resistant. In keeping
with the understanding that those temporarily resistant cells do not keep their re-
sistance for very long, we stated that all progeny of temporarily resistant cells were
sensitive. We did not distinguish between the phenotypes in the apoptotic stage.
Once cells entered that stage they did not interact with others until dying off and
leaving the system completely. We showed that our model provided a better fit for
the dynamics of the experimental data in [1].
Our second model incorporated the idea of a discrete representation for P-gp-
based drug resistance into a 2-dimensional spatial domain. We again extended the
work of [1] but this time into space rather than the cell cycle. We started with a
reaction diffusion system of two equations, one for sensitive cells u(x, t), and one for
resistant cells v(x, t). The density-inhibited proliferation allowed us to show that
the addition of the two equations led to a single Fisher-KPP equation with steady
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states at 0 and at full carrying capacity. In this case the tumor continued growing
toward the stable carrying capacity steady state.
We extended this approach with the addition of a temporarily resistant phe-
notype. We used this model to study the experimental data of [1]. We optimized
parameters and showed an improved fit to the experimental data compared with our
first model. Separately we added a cytotoxic drug to the model with only sensitive
and resistant cells. We showed that a constant drug infusion led to an almost fully
resistant tumor. We completed Chapter 4 by tying the two ideas together and writ-
ing a PDE system with four equations for sensitive cells, resistant cells, temporarily
resistant cells, and the drug. We then studied protocols of constant drug infusion
and on/off treatment protocols. We saught an optimal therapy and discovered that
the treatment protocol that minimizes the overall tumor size is a constant infusion
of a maximal drug dosage. This, however, led to a small tumor dominated by resis-
tant cancer cells. The treatment protocol that minimizes resistant cells was to not
treat the tumor at all, letting the sensitive cells control the resistant cell population.
With these results we have demonstrated that there is no optimal treatment that
can control the growth of the tumor while also controlling the resistant phenotype.
Our final model extended the integro-differential equation of Magal et. al [3],
in which tumor cells u(x, t) were assumed to have a continuous variable x describing
P-gp expression. The model included a Boltzmann type integral term describing
the transfer of P-gp between two cells. The integral contains two transfer rules,
describing two different efficiencies of transfer. In each transfer the cell with higher
resistance level transfers to the cell with lower resistance a portion that is a function
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of the difference in resistance levels.
We extended it by incorporating density-inhibited proliferation along with the
inclusion of a two dimensional spatial domain. We wrote our model as a single
partial differential equation with resistance variable p, 2-dimensional space variable
x, and time t. We first showed that our model is consistent with the results of [3]
in showing that the transfer of resistance leads to equal tumor cell density at each
level of resistance. We then incorporated a cytotoxic drug and studied its effects on
tumor heterogeneity. Under the assumption that more sensitive cells grow slightly
faster we saw that when no drug is present there is a supermajority of sensitive cells.
Once the drug is administered, however, the most resistant cells began to grow and
dominate. The makeup of the tumor changes, with the most sensitive cells in the
center surrounded by very resistant cells. We searched for optimal therapies and,
just as in our second model, we were able to show that there is no therapy that will
eradicate, or even control, the tumor growth when such resistant cells are present.
Continued work would first rely on access to more experimental data. We
were limited in our approaches by the lack of available data concerning P-gp and its
transfer between cells. In our cell cycle model we have not yet included any type of
drug, and our two PDE models only include a cytotoxic drug. Moving forward could
include combination therapies, with the inclusion of immunotherapy and cytostatic
drugs.
This work integrated mathematics and cancer biology. Mathematical oncol-
ogy is an exciting field continuing to grow and the work of mathematicians has
been invaluable to the medical community. The future discoveries and models by
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mathematicians will continue to be on the frontier of the fight to eradicate cancer.
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